Amicus Therapeutics Hits New 52-Week High of $14.48

Amicus Therapeutics, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 14.48 on April 8, 2026. This achievement underscores the company's notable performance over the past year, with a remarkable increase of 43.88%, outpacing the S&P 500's growth of 36.13% during the same period. With a market capitalization of USD 4,512 million, Amicus Therapeutics continues to navigate the competitive landscape of the biotechnology industry. The company's financial metrics reveal a debt-to-equity ratio of 0.59, indicating a manageable level of debt relative to its equity. However, it is important to note that the company is currently loss-making, as reflected in its negative return on equity of -5.36% and a price-to-book ratio of 19.58. As Amicus Therapeutics celebrates this new high, it remains focused on its strategic initiatives within the biotechnology field, marking a noteworthy chapter in its ongoing journey.